Advertisement
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of your Favored kind of pasta - 2Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- 3Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
- 4Vote In favor of Your Favored Comupter Game
- 5How grandchildren are stepping up to fill the caregiver gap
- Key Training: Picking a Significant for Monetary Achievement
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Pick Your Favored kind of soup
- Top Music and Dance Celebration: Which One Gets You Going?
- Ergonomic Office Seats for Work spaces
- Find Your Internal Culinary expert: Cooking Strategies and Recipes
- What's your biological age? Experts explain the benefits and risks of at-home tests
- Figuring out the Business venture Code: The Response to Building an Effective Startup
- Chemical leak in Oklahoma forces evacuations and leaves many ill
